PCI BIOTECH ASA NK 3
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company's technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vecto… Read more
Market Cap & Net Worth: PCI BIOTECH ASA NK 3 (4QG)
PCI BIOTECH ASA NK 3 (F:4QG) has a market capitalization of $505.75K (€492.71K) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #38077 globally and #5057 in its home market, demonstrating a -4.35% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PCI BIOTECH ASA NK 3's stock price €0.01 by its total outstanding shares 37326390 (37.33 Million).
PCI BIOTECH ASA NK 3 Market Cap History: 2015 to 2026
PCI BIOTECH ASA NK 3's market capitalization history from 2015 to 2026. Data shows change from $170.62 Million to $505.75K (-42.81% CAGR).
PCI BIOTECH ASA NK 3 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PCI BIOTECH ASA NK 3's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 4QG by Market Capitalization
Companies near PCI BIOTECH ASA NK 3 in the global market cap rankings as of March 18, 2026.
Key companies related to PCI BIOTECH ASA NK 3 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
PCI BIOTECH ASA NK 3 Historical Marketcap From 2015 to 2026
Between 2015 and today, PCI BIOTECH ASA NK 3's market cap moved from $170.62 Million to $ 505.75K, with a yearly change of -42.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €505.75K | -34.00% |
| 2025 | €766.29K | -79.36% |
| 2024 | €3.71 Million | -41.84% |
| 2023 | €6.38 Million | +13.49% |
| 2022 | €5.62 Million | -89.13% |
| 2021 | €51.72 Million | -47.27% |
| 2020 | €98.09 Million | -64.88% |
| 2019 | €279.31 Million | +191.60% |
| 2018 | €95.79 Million | -43.86% |
| 2017 | €170.62 Million | 0.00% |
| 2016 | €170.62 Million | 0.00% |
| 2015 | €170.62 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of PCI BIOTECH ASA NK 3 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $505.75K USD |
| MoneyControl | $505.75K USD |
| MarketWatch | $505.75K USD |
| marketcap.company | $505.75K USD |
| Reuters | $505.75K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.